Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
YOU ARE HERE: HOME > NEWS

Richmond Supports Groundbreaking Study in Alpha-1 Antitrypsin Deficiency (AATD) with Beam Therapeutics

3
December 2025

Richmond congratulates Beam Therapeutics on the preliminary results from the first three dose levels of its ongoing Phase 1/2 study...

View Articles

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

2
April 2025

Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...

View Articles

Richmond wins a Breakthrough Culture Award for committing to a people-first culture

13
March 2025

Richmond has been recognised as a great place to work and as one of the Breakthrough Culture Award winners for 2024.

View Articles

First patient enrolled in telehealth study, the Pathway Study

25
February 2025

The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...

View Articles

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

17
February 2025

We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...

View Articles

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

10
February 2025

The US-based Cardiac Safety Research Consortium has endorsed a project aimed at replacing the routine use of drugs...

View Articles

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

First patient enrolled in telehealth study, the Pathway Study

February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event
© 2024 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept